Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: Results from the GUSTO-V trial

European Heart Journal

Volumn 26, Issue 15, 2005, Pages 1506-1512

  Nallamothu, Brahmajee K ^a   Bates, Eric R ^a   Hochman, Judith S ^b   Granger, Christopher B ^c   Guetta, Victor ^d   Wilcox, Robert G ^e   White, Harvey D ^f   Armstrong, Paul W ^g   Savonitto, Stefano ^h   Jia, Gang ⁱ   Lincoff, A Michael ⁱ   Topol, Eric J ⁱ  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f GREEN LANE HOSPITAL   (New Zealand)

^g UNIVERSITY OF ALBERTA   (Canada)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute myocardial infarction; Fibrinolysis; Glycoprotein IIb IIIa receptor blockade; Heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN; RETEPLASE;

ARTICLE; BRAIN HEMORRHAGE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MEDICAL ASSESSMENT; MORTALITY; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONLINEAR SYSTEM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECORDING; STANDARD; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANGINA PECTORIS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; BUNDLE-BRANCH BLOCK; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS; RECURRENCE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 25444473620     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi181     Document Type: Article

References (16)

1. Hirsh J, Anand SS, Halperin JL et al. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018.
2. Granger CB, Hirsh J, Califf RM et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93:870-878.
3. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2004;44:E1-E211.
4. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.
5. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
6. Moliterno DJ, Califf RM, Aguirre FV et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-562.
7. Dalby M, Montalescot G, Bal dit Sollier C et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 2004;43:162-168.
8. Merlini PA, Repetto A, Andreoli AM et al. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase. Am J Cardiol 2004;93:195-198.
9. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
10. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
11. Narins CR. Heparin: how much in patients undergoing percutaneous coronary intervention? In: Ellis SG, Holmes DR, eds. Strategic Approaches in Coronary Intervention. Philadelphia PA: Lippincott Williams & Wilkins; 2000. p537-549.
12. Lee MS, Wali AU, Menon V et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002;14:91-101.
13. Anand SS, Yusuf S, Pogue J et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107:2884-2888.
14. Lauer MA, Houghtaling PL, Peterson JG et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2001;104:2772-2777.
15. Ross AM, Molhoek P, Lundegan C et al. Randomized comparison of enoxaparin, a low-molecular weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial heparin and aspirin reperfusion therapy (HART II). Circulation 2001;106:648-652.
16. Montalescot G, Collet JP, Tanguy ML et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-398.